Half-year Report

Rothschild & Co Continuation Fin
04 September 2023
 

Rothschild & Co Continuation Finance PLC

Half-yearly Report for the six-month period ended 30 June 2023

 

Interim Management Report

 

Summary of Important Events

 

Rothschild & Co Continuation Finance PLC (the "Company") is a wholly-owned subsidiary of N. M. Rothschild & Sons Limited ("NMR") and was incorporated on 30 August 2000 to operate as a finance vehicle for the benefit of NMR and its subsidiaries. 

 

The principal activity of the Company is the raising of finance for the purpose of lending it to NMR and other companies in NMR's group (the "Group"). The Company raises finance by the issue of perpetual subordinated notes guaranteed by NMR. 

 

Risks and Uncertainties

 

The principal risks of the Company are credit risk, liquidity risk and market risk. The Company follows the risk management policies of the parent undertaking, NMR.  

 

The Company's principal risk is credit exposure to NMR, as the notes issued by the Company have been guaranteed by, and funds have been on-lent to NMR. The Company is therefore reliant on the ability of NMR to meet its obligations under these lending arrangements. NMR is exposed to current market and geopolitical headwinds but, nevertheless, has sufficient liquidity to continue to operate for the next 12 months even in the scenario where revenue is significantly reduced. Management has considered the going concern basis of preparation as outlined in note 1 to the financial statements.

 

This half-yearly financial report has not been audited or reviewed by the Company's auditors pursuant to the Auditing Practices Board guidance on Review of Interim Financial Information. 

 

Responsibilities Statement

 

The Directors confirm that to the best of their knowledge:

 

-

The condensed set of financial statements has been prepared in accordance with IAS 34 Interim Financial Reporting; and

 

-

The interim management report includes a fair review of (i) the important events that have occurred during the first six months of the financial year, and their impact on the condensed set of financial statements, and (ii) the principal risks and uncertainties for the remaining six months of the financial year. 

 

By Order of the Board

Peter Barbour

Director

04/09/2023

 

Condensed Interim Statement of Comprehensive Income

For the six months ended 30 June 2023

 



6 months to

6 months to



30 June
2023

30 June
2022


Note

£

£

Interest income


2,053,754

693,444

Interest expense


(2,042,487)

(687,002)

Operating profit

 

11,267

6,442

Revaluation of loans

4

(3,476,570)

(24,717,418)

Revaluation of debt securities

9

3,470,275

24,722,319

Foreign exchange translation (losses)/gains


(7,337)

1,277

(Loss)/profit before tax

 

(2,365)

12,620

Taxation

3

(4,084)

(3,329)

(Loss)/profit for the financial period

 

(6,449)

9,291

Other comprehensive income


-

-

Total comprehensive (loss)/income for the financial period

 

(6,449)

9,291

 

Condensed Interim Statement of Changes in Equity

For the six months ended 30 June 2023

 


 

Share Capital

Retained Earnings

Total shareholders' equity


£

£

£

At 1 January 2023

100,000

324,190

424,190

Total comprehensive loss for the period

-

(6,449)

(6,449)

At 30 June 2023

100,000

317,741

417,741





At 1 January 2022

100,000

304,687

404,687

Total comprehensive income for the period

-

9,291

9,291

At 30 June 2022

100,000

313,978

413,978

 

Condensed Interim Balance Sheet

At 30 June 2023

 



At 30 June

At 31 December



2023

2023

2022

2022


Note

£

£

£

£

Non-current assets






Loan to parent undertaking

4


89,372,338


92,848,908

Current assets






Other financial assets

5

625,905


622,569


Cash and cash equivalents

6

269,013


265,057


 

 

894,918

 

887,626


Current liabilities






Current tax liability


(3,970)


(4,490)


Deferred tax liability

7

(42,519)


(37,915)


Other financial liabilities

8

(623,934)


(620,572)


Net current assets

 

 

224,495

 

224,649

Total assets less current liabilities

89,596,833


93,073,557

Non-current liabilities






Debt securities in issue

9


(89,179,092)


   (92,649,367)

Net assets

 

 

417,741

 

424,190

Shareholders' equity






Share capital

11


100,000


100,000

Retained earnings



317,741


324,190

Total shareholders' equity

 

417,741


424,190

 

 

Condensed Interim Cash Flow Statement

For the six months ended 30 June 2023



6 months to

6 months to



30 June
2023

30 June
2022


Note

£

£

Cash flow from operating activities




Net (loss)/profit for the financial period


(6,449)

9,291

Taxation


4,084

3,329

Net cash (outflow)/inflow from operating activities


(2,365)

12,620

 

Cash flow from financing activities

Net decrease in loans and interest receivable


 

 

3,473,234

 

 

24,431,389

Net decrease in debt securities in issue and interest payable


 

(3,466,913)

 

(24,436,447)

Net cash inflow/(outflow) from financing activities


6,321

(5,058)

 

Net increase in cash and cash equivalents

 

 

3,956

 

7,562

Cash and cash equivalents at beginning of half-year


265,057

250,897

Cash and cash equivalents at end of half-year

6

269,013

258,459

 

Interest receipts and payments during the period were as follows:

 


6 months to

6 months to


30 June 2023

30 June 2022


£

£

Interest received from parent undertaking

2,050,418

407,416

Interest paid to note holders

2,039,125

401,130

 

The Notes to the Condensed Interim Financial Statements form an integral part of the Condensed Interim Financial Statements.

 

 

Notes to the Condensed Interim Financial Statements

(forming part of the Condensed Interim Financial Statements)

For the six months ended 30 June 2023

 

1.   Basis of Preparation

 

The Condensed Interim Financial Statements are prepared and approved by the Directors in accordance with IAS 34 Interim Financial Reporting. The Condensed Interim Financial Statements are prepared under the historical cost accounting rules and should be read in conjunction with the annual financial statements for the year ended 31 December 2022, which have been prepared in accordance with International Financial Reporting Standards. 

 

The accounting policies and methods of valuation are identical to those applied in the financial statements for the year ended 31 December 2022.

 

Going Concern

Management has performed an assessment to determine whether there are any material uncertainties that could cast significant doubt on the ability of the Company to continue as a going concern. No significant issues have been noted. In reaching this conclusion, management considered:

 

-

The financial impact of the uncertainty on the Company's balance sheet;

 

-

The Company's liquidity position based on current and projected cash resources. The liquidity position has been assessed taking into account the forecast liquidity of NMR and its ability to continue to pay the interest on the intercompany loan provided by the Company.

 

Based on the above assessment of the Company's financial position, the Directors have concluded that the Company has adequate resources to continue in operational existence for the foreseeable future (for a period of at least twelve months after the date that the financial statements are signed). Accordingly, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

 

Financial Risk Management

The Company follows the financial risk management policies of the parent undertaking, NMR.  The key risks arising from the Company's activities involving financial instruments, which are monitored at the Group level, are as follows:

 

-

Credit risk - the risk of loss arising from client or counterparty default is not considered a significant risk to the Company as all asset balances are with other group companies as detailed in Note 12 Related Party Transactions. 

 

-

Market risk - exposure to changes in market variables such as interest rates, currency exchange rates, equity and debt prices is not considered significant as the terms of financial assets substantially match those of financial liabilities

 

-

Liquidity risk - the risk that the Company is unable to meet its obligations as they fall due or that it is unable to fund its commitments is not considered significant as the risk has been transferred to NMR.  As the funds on-lent to NMR have the same maturity dates as the notes issued, the Company's ability to meet its obligations in respect of notes issued by it is affected by NMR's ability to make payments to the Company.

 

 

2.   Directors' Emoluments

 

None of the directors received any remuneration in respect of their services to the Company during the period (2022: £nil). 

 

3.   Taxation

 


6 months to
30 June 2023

6 months to

30 June 2022


£

£

Current tax

520

(2,398)

Deferred tax

(4,604)

(931)

Total tax

(4,084)

(3,329)

 

The tax charge can be explained as follows:


6 months to

6 months to


30 June 2023

30 June 2022


£

£

(Loss)/profit before tax

(2,365)

12,620

United Kingdom corporation tax credit/(charge) at effective rate 22% (2022: 19%)

520

(2,398)

Deferred tax income statement charge

(4,604)

(931)

Tax charged for the period

(4,084)

(3,329)

 

 

4.   Non-Current Assets: Loan to Parent Undertaking

 


At 30 June

At 31 December


2023

2022


£

£

At beginning of period

92,848,908

114,548,269

Fair value movements

(3,476,570)

(21,699,361)

At end of period

89,372,338

92,848,908

Due



In 5 years or more

89,372,338

92,848,908

 

IFRS 9 requires the €150,000,000 loan to be carried at fair value which as at 30 June 2023 was £89,372,338 (at 31 December 2022: £92,848,908). On an amortised cost basis, the value of the loan at 30 June 2023 would be £128,830,562 (at 31 December 2022: £133,027,075). The fair values are based on the market value of the external debt securities (level 2).

 

The interest rate charged on the €150 million loan is EUR-TEC10-CNO plus 36 basis points, capped at 9.01% fixed on 05 February, 05 May, 05 August and 05 November each year. The interest rate on the above loan at 30 June 2023 was 3.18% (31 December 2022: 3.12%).

 

5.   Current Assets: Other Financial Assets

 


At 30 June

At 31 December


2023

2022


£

£

Interest receivable

625,905

622,569

 

 

6.   Cash and Cash Equivalents

 

At 30 June 2023 the Company held cash of £269,013 (31 December 2022: £265,057) at the parent undertaking.

 

7.   Deferred Income Taxes


At 30 June

At 31 December


2023

2022


£

£

At beginning of period

(37,915)

(35,869)

Recognised in income:

Income statement charge

 

(4,604)

 

(2,046)

At end of period

(42,519)

(37,915)

 

 

Deferred tax assets less liabilities are attributable to the following items:


At 30 June 2023

At 31 December 2022


£

£

Fair value of intra group loans

8,680,807

7,633,851

Fair value of debt securities in issue

(8,723,326)

(7,671,766)

 

(42,519)

(37,915)


Both the intra-group loans and debt securities in issue are taxed on an amortised cost basis of accounting and accordingly taxable/deductible temporary differences arise following the adoption of IFRS 9.

8.   Current Liabilities: Other Financial Liabilities

 


At 30 June

At 31 December


2023

2022


£

£

Interest payable

623,934

620,572

 

 

9.   Non-Current Liabilities: Debt Securities in Issue

 


At 30 June

At 31 December


2023

2022


£

£

At beginning of period

92,649,367

114,359,489

Fair value movements

(3,470,275)

(21,710,122)

At end of period

89,179,092

92,649,367

Due



In 5 years or more

89,179,092

92,649,367

 

Given the IFRS 9 requirement to fair value the related loans, the Company has elected to fair value the debt securities in issue, which as at 30 June 2023 was £89,179,092 (at 31 December 2022: £92,649,367). On an amortised cost basis, the value of the debt securities in issue at 30 June 2023 would be £128,830,562 (at 31 December 2022: £133,027,075). Consistent with the prior period, the fair value was derived from quoted market prices at the balance sheet date. In accordance with IFRS 13 and due to a reduction in the frequency and volume of transactions observed in the immediate run up to the period end, the fair value is considered to be level 2 as at 30 June 2023 (2022: level 1).

 

The interest rate payable on the €150 million Perpetual Subordinated Notes is EUR-TEC10-CNO plus 35 basis points, capped at 9 per cent, fixed on 05 February, 05 May, 05 August and 05 November each year. From and including the interest payment date falling in August 2016 and every interest payment date thereafter, the Company may redeem all (i.e. not in part) of the Perpetual Subordinated Notes at their principal amount. 

 

The interest rate on the above notes at 30 June 2023 was 3.17% (31 December 2022: 3.11%).

 

10.   Maturity of Financial Liabilities

 

The following table shows contractual cash flows payable by the Company on the perpetual subordinated notes classified by remaining contractual maturity at the balance sheet date. Interest cash flows on perpetual subordinated notes are shown up to five years only, with the principal balance being shown in the perpetual column.

 

At 30 June 2023



3 months







or less

1 year

5 years





but not

or less

or less





payable on

but over

but over




Demand

demand

3 months

1 year

Perpetual

Total


£

£

£

£

£

£

Perpetual subordinated notes

 

-

 

1,020,982

 

3,062,947

 

16,335,715

 

128,830,562

 

149,250,206

 

At 31 December 2022



3 months







or less

1 year

5 years





but not

or less

or less





payable on

but over

but over




Demand

demand

3 months

1 year

Perpetual

Total


£

£

£

£

£

£

Perpetual subordinated notes

 

-

 

1,034,286

 

3,102,857

 

16,548,568

 

133,027,075

 

153,712,786

 

 

11.   Share Capital

 


At 30 June

At 31 December


2023

2022


£

£

Authorised, allotted, called up and fully paid



100,000 Ordinary shares of £1 each

100,000

100,000

 

 

12.   Related Party Transactions

 

Parties are considered to be related if one party controls, is controlled by or has the ability to exercise significant influence over the other party. This includes key management personnel, the parent company, subsidiaries and fellow subsidiaries. 

 

Amounts receivable from related parties at the period end were as follows:

 


At 30 June

At 31 December


2023

2022


£

£

Cash and cash equivalents at parent undertaking

269,013

265,057

Accrued interest receivable from parent undertaking

625,905

622,569

Loans to parent undertaking

89,372,338

92,848,908

 

 

Amounts recognised in the condensed statement of comprehensive income in respect of related party transactions were as follows:

 


6 months to

6 months to


30 June 2023

30 June 2022


£

£

Interest income from parent undertaking

2,053,754

693,444

 

There were no loans made to Directors during the period (6 months to 30 June 2022: none) and no balances outstanding at the period end (at 31 December 2022: £nil). There were no employees of the Company during the period (6 months to 30 June 2022: none).

 

 

13.    Parent Undertaking and Ultimate Holding Company and Registered Office

 

The largest group in which the results of the Company are consolidated is that headed by Rothschild & Co Concordia SAS, incorporated in France, and whose registered office is at 23bis, Avenue de Messine, 75008 Paris.  The smallest group in which they are consolidated is that headed by Rothschild & Co SCA, a French public limited partnership whose registered office is also at 23bis, Avenue de Messine, 75008 Paris. The accounts are available on the Rothschild & Co website at www.rothschildandco.com.

 

The Company's immediate parent company is N. M. Rothschild and Sons Limited, incorporated in England and Wales and whose registered office is at New Court, St Swithins Lane, London, EC7N 8AL. 

 

The Company's registered office is located at New Court, St Swithin's Lane, London, EC4N 8AL. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings